Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24323532 | 0.82 | L3MBTL1 (0.48) | DPP4KMT2AMEN1L3MBTL1CYP2D6 | |
| SCHEMBL24818614 | 0.82 | DPP4 (0.47) | DPP4KMT2ATGM2MEN1L3MBTL1 | |
| SCHEMBL3311749 | 0.80 | HRH2 (0.35) | DPP4KMT2ATGM2MEN1POLB | |
| SCHEMBL3748944 | 0.79 | LMNA (0.40) | DPP4KMT2AMEN1L3MBTL1CYP2D6 | |
| SCHEMBL13422266 | 0.78 | HTR1A (0.46) | DPP4KMT2ATGM2L3MBTL1KDM4E | |
| SCHEMBL3736947 | 0.78 | MAOA (0.35) | DPP4KMT2AMEN1CYP2D6KDM4E | |
| SCHEMBL5348 | 0.77 | BLM (0.44) | KMT2AMEN1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL24322565 | 0.77 | HTT (0.56) | POLBL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL3316350 | 0.77 | FAP (0.41) | DPP4ALDH1A1 | |
| SCHEMBL18330367 | 0.76 | ALDH1A1 (0.56) | DPP4KMT2AMEN1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | DPP4 694/4885KMT2A 3784/4885TGM2 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.